Andrew Blauvelt, MD, MBA, presented attendees with an update on the AD pipeline. Dr. Blauvelt reviewed recent research on biologics such as tralokinumab, an anti-IL-13 monoclonal antibody (mAb), lebrikizumab, an anti-IL-13 mAb, and nemolizumab, an anti-IL-31 receptor A mAb. Dr. Blauvelt discussed other studies on monoclonal antibodies for AD targeting IL-5, IL-22, TSLP, IL-17C, IL-1alpha, IL-33, and OX40. In addition, Dr. Blauvelt discussed research on the JAK1 Blockers Baricitinib, upadactinib, and PF-04965842. Additional potential therapies discussed include ASN002, ZPL-389, and apremilast. Dr. Blauvelt also covered new topical drugs for AD, including JAK inhibitors, PDE4 inhibitors, and tapinarof.
Eric Simpson, MD, MCR, provided an update on dupilumab. Topics discussed by Dr. Simpson include:
- When to use systemic therapy
- What to tell patients to expect with systemic therapy
- Are there patients who should not be put on dupilumab?
- Should we check labs?
- How to treat dupilumab conjunctivitis
- How to treat facial resistance or flares
- How long will patients stay on dupilumab?
- Other uses for dupilumab
- Combination treatment
Lawrence F. Eichenfield, MD, provided attendees with an update on pediatric AD.